Compare PDEX & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PDEX | BDTX |
|---|---|---|
| Founded | 1978 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.5M | 116.8M |
| IPO Year | 1995 | 2020 |
| Metric | PDEX | BDTX |
|---|---|---|
| Price | $48.46 | $2.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $56.00 | $10.40 |
| AVG Volume (30 Days) | 17.6K | ★ 564.6K |
| Earning Date | 05-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 345.00 | 32.45 |
| EPS | ★ 2.07 | 0.65 |
| Revenue | ★ $66,593,000.00 | N/A |
| Revenue This Year | $7.22 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.62 | ★ $3.28 |
| Revenue Growth | ★ 23.68 | N/A |
| 52 Week Low | $23.52 | $1.20 |
| 52 Week High | $70.26 | $4.94 |
| Indicator | PDEX | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 66.92 | 40.78 |
| Support Level | $37.39 | $1.93 |
| Resistance Level | $48.33 | $2.67 |
| Average True Range (ATR) | 2.97 | 0.14 |
| MACD | 0.21 | -0.01 |
| Stochastic Oscillator | 70.50 | 26.76 |
Pro-Dex Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers (OEMs) to various countries. Its product portfolio includes autoclavable, battery-powered, electric, and multi-function surgical drivers and shavers used mainly in orthopedic, thoracic, and craniomaxillofacial markets. The company also provides engineering, quality, regulatory consulting services, and manufactures rotary air motors utilized in various industries. Operating out of ISO-certified facilities in California, Pro-Dex serves hospitals, medical labs, and high-tech manufacturers, generating revenue through sales of surgical instruments and related services.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.